Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Positherapy with F-18-FDG improves survival, reduces tumor growth in mice
April 7th, 2005
Specialists in nuclear medicine at Yeshiva University's Albert Einstein College of Medicine report that in a mouse model of breast cancer, positron therapy with F-18-2-deoxy-2-fluoro-D-glucose significantly prolonged survival and decreased mammary tumor growth rate compared to controls. R.M. Moadel and colleagues wrote, "Novel therapies are needed for [breast cancer] patients when standard treatments are ineffective. We have recently shown on a cellular level the therapeutic potential of positrons in malignancy. Here, we report for the first time positron therapy with F-18-2-deoxy-2-fluoro-D-glucose (F-18-FDG) in a breast cancer animal model to affect tumor growth rate...
Source: Women's Health Weekly (2005-04-07)
|
